Lexology February 20, 2025
Morgan Lewis & Bockius LLP

In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed and Health Law Scan, focusing on issues impacting the rare disease community.

The value of merger and acquisition (M&A) deals of rare disease companies has increased significantly over the past few years (from $18.9 billion in 2019 to $50.6 billion in 2022 according to a 2024 article in Nature Reviews Drug Discovery). This combined with recent billion-dollar acquisitions in the rare disease space have piqued the interest of large pharmaceutical companies, as well as investors, and may be indicative of further growth of this life sciences sector in the years ahead. This article analyses some of the...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Mergers & Acquisitions / JV, Provider, Trends
Thermo Fisher Beefs Up in Bioprocessing With $4B Acquisition of Solventum Biz Segment
The Top IPO And M&A Candidates In Cloud And AI Infrastructure For 2025
California to Reconsider Restrictions on Private Equity Influence in Medicine and Dentistry
10 trends defining hospital consolidation
Private equity investment in healthcare remained steady in 2024: report

Share This Article